Method for cell adhesion and wound healing

Abstract

The present invention relates to a method for cell adhesion and wound healing with internal domains of βig-h3. Particularly, the present invention relates to the method of using recombinant proteins comprising one or more of 2 nd or 4 th internal domain of βig-h3 for cell adhesion and wound healing, wherein the 2 nd or 4 th internal domain of βig-h3 has aspartic acid and isoleucine essential for interaction with integrin which represent a high homology in base sequence of βig-h3 internal domains. The recombinant proteins comprising one or more 2 nd or 4 th internal domain of βig-h3 are effective for cell adhesion and wound healing by itself and can be used for developing cell culture medium and wound healing agent.

1 - 15 . (canceled) 
     
     
         16 . A recombinant protein mediating cell adhesion comprising one or more copies of the 4 th  fas-1 domain of βig-h3, wherein the recombinant protein does not include full-length βig-h3 protein. 
     
     
         17 . The recombinant protein according to  claim 16 , wherein the 4 th  fas-1 domain of βig-h3 consists of the amino acid sequence 498-637 of human βig-h3 (SEQ ID NO: 26). 
     
     
         18 . The recombinant protein according to  claim 16 , wherein the recombinant protein comprises the amino acid sequence 502-637 of human βig-h3 (SEQ ID NO:27) in quadraplicate. 
     
     
         19 . The recombinant protein according to  claim 16 , wherein the recombinant further comprises one or more copies of the 2 fas-1 domain of βig-h3. 
     
     
         20 . A recombinant protein mediating cell adhesion comprising two or more copies of the 2 nd  and/or the 4 th  fas-1 domain of βig-h3. 
     
     
         21 . The recombinant protein according to  claim 20 , wherein the 2 nd  fas-1 domain of βig-h3 consists of the amino acid sequence 237-377 of βig-h3 (SEQ ID NO: 24). 
     
     
         22 . The recombinant protein according to  claim 20 , wherein the 4 th  fas-1 domain of βig-h3 consists of the amino acid sequence 498-637 of βig-h3 (SEQ ID NO: 26). 
     
     
         23 . The recombinant protein according to  claim 20 , wherein the recombinant protein comprises the amino acid sequence 502-637 of βig-h3 (SEQ ID NO:27) in quadraplicate. 
     
     
         24 . A recombinant protein consisting of one or more copies of the 2 nd  and/or 4 th  fas-1 domain of βig-h3. 
     
     
         25 . The recombinant protein according to  claim 24 , wherein the 2 nd  fas-1 domain of βig-h3 consists of the amino acid sequence 237-377 of βig-h3 (SEQ ID NO: 24). 
     
     
         26 . The recombinant protein according to  claim 24 , wherein the 4 th  fas-1 domain of βig-h3 consists of the amino acid sequence 498-637 of βig-h3 (SEQ ID NO: 26). 
     
     
         27 . The recombinant protein according to  claim 24 , wherein the recombinant protein consists of the amino acid sequence 502-637 of βig-h3 (SEQ ID NO:27) in quadraplicate. 
     
     
         28 . A wound healing agent comprising a therapeutically effective amount of the recombinant protein of  claim 16 . 
     
     
         29 . A wound healing agent comprising a therapeutically effective amount of the recombinant protein of  claim 20 . 
     
     
         30 . A wound healing agent comprising a therapeutically effective amount of the recombinant protein of  claim 24 . 
     
     
         31 . A solid support coated with the recombinant protein of  claim 16 . 
     
     
         32 . A solid support coated with the recombinant protein of  claim 20 . 
     
     
         33 . A solid support coated with the recombinant protein of  claim 24 .